Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of ScienceBusiness Wire • 11/10/25
Bayer to Present New Data for KERENDIA® (finerenone) in People with Chronic Kidney Disease and Type 1 or Type 2 Diabetes at American Society of Nephrology (ASN) Kidney Week 2025Business Wire • 11/03/25
Bayer's Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to MenopauseBusiness Wire • 10/24/25
Bayer Reports Positive Data on Cell Therapy for Parkinson's DiseaseZacks Investment Research • 10/08/25
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump DealZacks Investment Research • 10/08/25
Hesperos and Bayer Consumer Health Develop First Human-on-a-Chip® Model of Stress-Induced Cognitive DysfunctionBusiness Wire • 10/07/25
Bayer Canada Announces New Distribution Partnership for ADALAT® XL® (nifedipine extended-release tablets) 30 mg Tablets in CanadaBusiness Wire • 09/25/25
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025Business Wire • 09/25/25
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's DiseaseBusiness Wire • 09/22/25
Expert with Bayer Discusses the U.S. Launch of Aspirina Families with YourUpdateTVGlobeNewsWire • 09/16/25